As a result, Albany Molecular Research (AMRI) will receive a $1.5 million milestone payment from Bristol-Myers Squibb Company for the nomination of this clinical candidate, marking the third
The company said that it is reaffirming its adjusted diluted earnings per share (EPS) guidance for 2008, 2009 and 2010 of $0.47 to $0.53, $0.90 to $1.10 and
The alliance is based on discoveries from a collaboration between Arbor Vita (AVC) and NoNO of Toronto, and will explore the use of the companies’ NA-1 compound as
North American Scientific said that the proceeds from the sale of this product line will provide the company with important non-dilutive capital to invest in ongoing operations. John
Finfacts reported that the Minister for Finance, Brian Lenihan has announced that Boston Scientific will invest E50m, with the support of IDA Ireland, in strategic R&D at its
Mr Vaters joins Orthofix after almost four years as a senior executive at Inamed, where he was executive vice president, CFO and head of strategy and corporate development.
The first study has demonstrated a high degree of overall concordance – 95% – between central immunohistochemistry (IHC) and quantitative RT-PCR using Oncotype DX for determining HER2 status.
The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45mg of COL-144 or placebo as an intravenous infusion over 20
In the study, patients experiencing migraine with aura achieved sustained relief from their headaches, representing a potentially differentiated treatment profile from current migraine therapies. Data from the Phase
In this new role, Mr Ross will oversee Axial Biotech’s global efforts to identify, evaluate, and pursue new diagnostic opportunities and will help to coordinate the company’s long-term
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.